Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:16:56.356Z.
Calculation as of: 2026-10-06T16:16:56.356Z.
Quote observation: 2026-10-06T16:14:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $242.52M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.44M | N/A | 2.31 | 2.31 | 2.31 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $244.33M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $244.52M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $245.30M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $245.55M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.98M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $239.19M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $241.59M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
